Research from the University of Texas Health Science Center at San Antonio has shed light on the role of a critical enzyme, known as apolipoprotein B mRNA-editing enzyme, catalytic polypeptide, or APOBECs, in cancer treatment. These enzymes, which typically function to protect the body from viral infections, can become detrimental when they malfunction in the context of cancer.
According to Reuben S. Harris, PhD, chair of the Department of Biochemistry and Structural Biology at UT Health San Antonio, APOBECs are essential for mutating viral DNA to prevent infections. “So from the virus perspective, these enzymes protect us,” Harris explained. However, in many cancer cases, these same enzymes can become dysregulated, leading to unintended consequences. “Instead of destroying viruses, they end up damaging our genomes,” he added.
Harris emphasized that while APOBECs serve a protective function, they can transform into “villains” in the fight against cancer. Their hyperactivity can lead to significant genomic instability, which is a common characteristic of many tumors. “In cancer, the good guys can become villains that do catastrophic damage,” he stated.
Targeting APOBECs in Cancer Therapy
The research team proposes that addressing the activity of APOBECs during treatment could significantly improve patient outcomes. Often, the standard care for tumors includes surgical resection followed by therapy. Harris suggests that this is an opportune moment to intervene and inhibit the action of these enzymes. “If we could shut off these enzymes after an APOBEC positive tumor is removed, we could reduce the risk that the cancer will return, spread, or develop resistance to medication,” he said.
This approach could potentially mitigate adverse events associated with cancer treatment, making it less likely for patients to experience recurrence or complications from their illness. “If we can stop that, we can make all of these adverse events much less likely to happen,” Harris remarked. The prospect of harnessing the power of APOBECs for therapeutic purposes has generated considerable excitement within the research community.
The collaboration between TPR and the University of Texas Health Science Center at San Antonio aims to explore how scientific discoveries in San Antonio are advancing medical practices globally. As research continues to evolve, the implications of targeting APOBECs could lead to innovative strategies that enhance the efficacy of cancer treatments.
This investigation into the dual nature of APOBECs highlights the complexity of the immune response and its implications for cancer therapy. By understanding and manipulating these enzymes, scientists hope to pave the way for improved treatment protocols, ultimately benefiting patients facing the challenges of cancer.